Inside Precision Medicine September 6, 2024
Xenotransplantation pioneer eGenesis has closed a $191 million Series D financing led by Lux Capital. The proceeds will go toward advancing eGenesis’s lead candidate for kidney transplant.
The company has already garnered headlines for its pig organ transplants. In March 2024, eGenesis announced the world’s first successful porcine kidney transplant in a living patient. The transplant was FDA authorized under the Expanded Access pathway and performed by a surgical team at the Massachusetts General Hospital.
eGenesis’ latest financing was led by Lux Capital, with participation from existing investors ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer as well as new investors DaVita, Eisai Innovation, NATCO Pharmaceuticals, and Parkwood Corporation.
“This financing...
Today's Sponsors
Today's Sponsor